First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings
Roche’s Donald Mason explains how automation, standardization, and core-lab integration could help clinical laboratories expand access to mass spectrometry-based testing
Highlighting innovations in mass spectrometry, next-generation sequencing, digital pathology and AI diagnostics
Roche launches the first fully automated high-throughput test for Hepatitis D virus detection and monitoring
The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets
Roche will showcase new trontinemab clinical data, Phase III prevention studies, neuroinflammatory research, and blood-based Alzheimer’s diagnostics including Elecsys® pTau217 and pTau181
Agreement expands Roche’s oncology pipeline with a potential best in class targeted protein degrader for B cell malignancies and beyond
New assay identifies patients with PTEN protein loss who may benefit from targeted treatment
Rapid-response assay supports early detection and surveillance during ongoing Ebola outbreak
Late-stage data highlight efficacy and safety of investigational therapies enicepatide and petrelintide for weight management
New digital and biomarker-integrated solution supports early detection, risk assessment, and disease monitoring
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages
Elecsys pTau217 is the first single-assay blood test designed to identify or rule out amyloid pathology across primary and secondary care
Acquisition strengthens Roche’s digital pathology and companion diagnostic portfolio to advance precision medicine
How Roche and Disease Management Consulting empower laboratory professionals to drive strategic value in healthcare systems
Minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods
The cobas c 703 and cobas ISE neo analytical units deliver higher testing capacity and increased automation, helping to improve laboratory workflows and advance patient care
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences
The point-of-care test detects and differentiates between three types of Bordetella infection that can cause similar cough symptoms, ensuring patients receive the right diagnosis at the earliest opportunity
This tool will be launched as part of Roche’s new chronic kidney disease algorithm panel to support care across the stages of the disease which affects 700 million people globally
Roche has been recognized as No. 1 in seven of nine award categories
Elecsys pTau181 is the first in vitro diagnostic regulation (IVDR)-certified test to rule out Alzheimer’s associated amyloid pathology
Data to be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress
